sbrt-enhanced intermittent androgen deprivation therapy in nodal oligorecurrent prostate cancer
Published 1 month ago • 84 plays • Length 10:30Download video MP4
Download video MP3
Similar videos
-
10:38
updates in treatment using adt and anti-androgens
-
19:44
combining therapy with sbrt and brachytherapy
-
18:34
testosterone therapy in men with biochemical recurrence and metastatic prostate cancer
-
27:50
new concepts in adt
-
16:50
treatment of oligometastatic disease
-
8:59
role of adt with radiation
-
14:29
comparative outcomes: prostate brachytherapy vs. ebrt vs. sbrt for low/intermediate risk disease
-
33:30
minimizing morbidity and maximizing outcomes with adt
-
32:15
intermittent androgen deprivation therapy in prostate cancer?
-
11:48
cardiovascular implications in the treatment of prostate cancer
-
8:36
the importance of diagnosing and treating oligometastatic prostate cancer and adt usage
-
19:37
combining brachytherapy with sbrt
-
17:38
androgen deprivation therapy (adt) and cognitive health
-
27:05
adt for prostate cancer: agonists vs antagonists
-
7:17
understanding metastatic castration-resistant prostate cancer
-
19:56
recognizing and managing side effects of androgen deprivation therapy (adt)
-
6:14
intermittent versus continuous androgen-deprivation therapy in prostate cancer
-
4:09
intermittent versus continuous androgen deprivation therapy in prostate cancer
-
12:30
long term morbidity mortality of adt and radiation therapy